Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

The Phase 1 clinical study is expected to enroll approximately 24 healthy adult volunteers. The primary objectives of the study are to characterize the pharmacokinetic release profile of the nalmefene ...

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Positive, early results ...

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion ...

Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...

ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearance Results showed excellent consistency between ...

BioAtla, Inc. has announced promising preliminary results from a Phase 1 clinical trial of BA3182, a dual-Conditionally Active Biologic bispecific T-cell engager targeting EpCAM and CD3, for treating ...